Browse
Submit Data
Databases
API
Help

Dataset Information

22 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancer

ABSTRACT: Interventions: investigational material(s) Generic name etc : Bevacizumab INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Injection Primary outcome(s): Initial safety, PK parameter of bevacizumab Study Design: Open, Single Arm study

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 99192 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancer

Project description:Interventions: investigational material(s) Generic name etc : Bevacizumab INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Injection Primary outcome(s): Safety Study Design: Open, Single Arm study

| 99347 | ecrin-mdr-crc

A Randomized Phase III Trial of SOX/Bevacizumab versus FOLFOX/Bevacizmab in Treating Patients with Metastatic Colorectal Cancer (SOFT).

Project description:Interventions: investigational material(s) Generic name etc : S-1 (tegafur + gimeracil + oteracil potassium) INN of investigational material : S-1: tegafur, gimeracil, oteracil potassium Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : 40-60 mg bid day 1 (evening) - day 15 (morning). Repeat cycles every 3 weeks Generic name etc : L-OHP (Oxaliplatin) INN of investigational material : oxaliplatin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 130 mg/m2 IV on day 1. Repeat cycles every 3 weeks Generic name etc : BV (Bevacizumab) INN of investigational material : bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 7.5 mg/kg IV on day 1. Repeat cycles every 3 weeks control material(s) Generic name etc : 5-FU (Fluorouracil) INN of investigational material : fluorouracil Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : 400 mg/m2 IV bolus on day 1, followed by 2400 mg/m2 over 46 hours. Repeat cycles every 2 weeks. Generic name etc : l-LV (Levofolinate calcium) INN of investigational material : folic acid Therapeutic category code : 392 Antidotes Dosage and Administration for Investigational material : 200 mg IV on day 1. Repeat cycles every 2 weeks. Generic name etc : L-OHP (Oxaliplatin) INN of investigational material : oxaliplatin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 85 mg/m2 IV on day 1. Repeat cycles every 2 weeks. Generic name etc : BV (Bevacizumab) INN of investigational material : bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage Primary outcome(s): Progression free survival(PFS) Study Design: Randomized, open-label, comparative study

| 97778 | ecrin-mdr-crc

ONO-4538/CA2099X8 Phase 2/3 Study(ONO-4538-72/CA2099X8)

Project description:Interventions: investigational material(s) Generic name etc : ONO-4538/BMS-936558 INN of investigational material : Nivolumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous administration control material(s) Generic name etc : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab INN of investigational material : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Intravenous administration Primary outcome(s): efficacy PFS Study Design: Randomized, open-label

| 102159 | ecrin-mdr-crc

NK012 phase II clinical study

Project description:Interventions: investigational material(s) Generic name etc : NK012(other antitumor agents) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous

| 98783 | ecrin-mdr-crc

Phase I/II study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in advanced and/or metastatic colorectal cancer

Project description:Interventions: investigational material(s) Generic name etc : Capecitabine|Oxaliplatin|Bevacizumab INN of investigational material : Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Capecitabine: oral administration Oxaliplatin and Bevacizumab: injection Primary outcome(s): Response Rate, Safety Study Design: Open, Single Arm study

| 99396 | ecrin-mdr-crc

A feasibility study of Oxaliplatin(L-OHP)in combination with infusional 5-FU/l-LV(FOLFOX4 regimen)for advanced colorectal cancer

Project description:Interventions: investigational material(s) Generic name etc : Oxaliplatin|Fluorouracil|Levofolinate calcium INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous infusion Primary outcome(s): Safety Study Design: Open-label, multicenter trial

| 99274 | ecrin-mdr-crc

Post-Marketing Study of FOLFIRI Therapy + Avastin (Bevacizumab) in Patients with Metastatic Colorectal Cancer

Project description:Interventions: investigational material(s) Generic name etc : Avastin INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 5 mg/kg/2W Primary outcome(s): Response rate, safety Study Design: Open, Single arm

| 99618 | ecrin-mdr-crc

Phase I/II trial of YHI-1003 plus Capecitabine

Project description:Interventions: investigational material(s) Generic name etc : YHI-1003 INN of investigational material : Perifosine Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : oral Primary outcome(s): safety CTCAE v4.0 Study Design: open-label, multicenter trial

| 100604 | ecrin-mdr-crc

Phase 2/3 study of fluoropyrimidine and irinotecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab as second-line for metastatic colorectal cancer (TRUSTY)

Project description:Interventions: investigational material(s) Generic name etc : trifluridine/tipiracil INN of investigational material : trifluridine/tipiracil Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Trifluridine/tipiracil was given in a dose of 35-75 mg twice daily (after breakfast and dinner) (70-150 mg/day) from after dinner on Day 1 to after breakfast on Day 6 and from after dinner on Day 8 to after breakfast on Day 13. Treatment was given orally for 5 consecutive days followed by a 2-day rest. This treatment was repeated twice, followed by a 14-day rest. This 28-day cycle was repeated until the criteria for withdrawal of the study treatment were met. Generic name etc : bevacizumab INN of investigational material : bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Bevacizumab 5 mg/kg was given as a 30-min continuous intravenous infusion on Day 1 and Day 15. control material(s) Generic name etc : fluorouracil INN of investigational material : fluorouracil Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : [Treatment with FOLFIRI + bevacizumab] Fluorouracil 400 mg/m2 was given by rapid intravenous injection on Day 1, followed by a 46-h continuous intravenous infusion of 2400 mg/m2. Each cycle was 14 days, and treatment was repeated until the criteria for withdrawal of the study treatment were met. Generic name etc : TS-1(tegafur + gimeracil + oteracil potassium) INN of investigational material : TS-1(tegafur + gimeracil + oteracil potassium) Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : [Treatment with TS-1+ irinotecan +bevacizumab (3- Primary outcome(s): efficacy Overall survival Study Design: Randomized, open-label, comparative study

| 98099 | ecrin-mdr-crc

DS-Screen

Project description:Interventions: investigational material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : - control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : - Primary outcome(s): exploratory FGFR2 and HER2 protein expression IHC Study Design: Observational study

| 98039 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data